TY - JOUR

T1 - Small animal disease surveillance

T2 - Gastrointestinal disease, antibacterial prescription and Tritrichomonas foetus

AU - Singleton, D.A.

AU - Arsevska, E.

AU - Smyth, S.

AU - Barker, E.N.

AU - Jewell, C.

AU - Brant, B.

AU - Sánchez-Vizcaíno, F.

AU - Dawson, S.

AU - Pinchbeck, G.L.

AU - Noble, P.J.M.

AU - Jones, P.H.

AU - Radford, A.D.

N1 - Export Date: 28 February 2019 CODEN: VETRA Correspondence Address: Singleton, D.A.; Institute of Infection and Global HealthUnited States; email: D.A.Singleton@liverpool.ac.uk Funding details: Biotechnology and Biological Sciences Research Council, BBSRC Funding text 1: SAVSNET is based at the University of Liverpool. It is currently funded by the Biotechnology and Biological Sciences Research Council and the British Small Animal Veterinary Association. The SAVSNET team is grateful to the veterinary practices and diagnostic laboratories that provide health data and without whose support these reports would not be possible. It wishes to thank Batt Laboratories, BioBest, CAPL, CTDS, CVS, Idexx, Lab Services, Langford Veterinary Services, NationWide Laboratory Services, PTDS, SRUC, TDDS, Teleos, Test A Pet and Microbiology Diagnostics Laboratory at University of Liverpool, and VetSolutions (the suppliers of RoboVet and PremVet). The team would also like to thank Susan Bolan, SAVSNET project administrator, for her help and support.

PY - 2019/2/14

Y1 - 2019/2/14

N2 - Report summary:• Presentation for investigation and/or treatment of gastrointestinal (GI) disease comprised 3.0 per cent, 2.0 per cent and 1.9 per cent of total dog, cat and rabbit consultations respectively between 1 April 2017 and 31 October 2018• Diarrhoea and vomiting without blood were the most frequently reported GI disease clinical signs (43.0 and 36.6 per cent in dogs, and 35.9 and 37.7 per cent in cats respectively)• The proportion of GI disease consultations which prescribed antibiotics authorised for systemic administration (including oral and injectable formulations) decreased between April 2014 and October 2018• The proportion of GI disease consultations which dispensed nutraceutical products advertised as being effective at managing primary GI disease (including prebiotics, probiotics etc.) increased between April 2014 and October 2018• Between January 2011 and August 2018, 13.5 per cent of 20,194 feline faecal samples submitted to UK-based diagnostic laboratories tested positive for presence of Tritrichomonas foetus• The proportion of feline sample submissions testing positive for T.foetus decreased between 2011 and 2018

AB - Report summary:• Presentation for investigation and/or treatment of gastrointestinal (GI) disease comprised 3.0 per cent, 2.0 per cent and 1.9 per cent of total dog, cat and rabbit consultations respectively between 1 April 2017 and 31 October 2018• Diarrhoea and vomiting without blood were the most frequently reported GI disease clinical signs (43.0 and 36.6 per cent in dogs, and 35.9 and 37.7 per cent in cats respectively)• The proportion of GI disease consultations which prescribed antibiotics authorised for systemic administration (including oral and injectable formulations) decreased between April 2014 and October 2018• The proportion of GI disease consultations which dispensed nutraceutical products advertised as being effective at managing primary GI disease (including prebiotics, probiotics etc.) increased between April 2014 and October 2018• Between January 2011 and August 2018, 13.5 per cent of 20,194 feline faecal samples submitted to UK-based diagnostic laboratories tested positive for presence of Tritrichomonas foetus• The proportion of feline sample submissions testing positive for T.foetus decreased between 2011 and 2018

U2 - 10.1136/vr.l722

DO - 10.1136/vr.l722

M3 - Journal article

VL - 184

SP - 211

EP - 216

JO - Veterinary Record

JF - Veterinary Record

SN - 0042-4900

IS - 7

ER -